Tuesday, March 17, 2015

Disconnect between brain and fingers.

Hi to All!

I have not posted alot lately regarding me and my journey with Alzheimer's. I am starting to have great difficulty in getting what is in my brain cell to my fingers. Somewhere on it's journey from brain to fingers it gets lost or just plain nothing. I have been fortunate for sometime to be able to communicate here with all of you. But it seems the disease is starting to take what it feels rightfully belongs to it. It is taking a physical toll on me as well. Greedy bastard that it is. I do not write much about going here or there, because I feel that my mission on this blog is to talk about what the disease really does.
Once again I have started getting this crap on how to prevent Alzheimer's or dementia in and of it self. How to cure it. Boils down to the same old bullshit nothing. The new studies and trials that promise so much, suddenly you stop hearing about them, why because they all fail. To many restrictions on reasearch and movement of possible drugs to the market. Smaller brained powered individuals then myfelf  making life decisions for you and me, makes no sense.
I guess 57+ people dieing each day from the Alzheimer's is of no importance to those that try to govern our lives and tell us how they will take care of us. I say stick it up your already clogged lower intestine. We need to force the issue. Not by kissing up to them, but getting on the unemployment lines and start our revolution to first an understanding of the cause, then how to prevent it where we can (if that is possible), find real treatments that work and not just mask symptoms until they stop and leave the person hanging on the cliff. Sounds a bit political, right? Well the time has come for us to go into action. It is clear those claiming to help us, really have not come much more than a foot in well over 100 years.

God Bless & Keep You & This Country of Ours!
joe

Sunday, March 01, 2015

From Alzheimer's & Dementia Weekly.

FEBRUARY 18, 2015

What is Vascular Dementia?

Vascular dementia is one of the 3 leading causes of dementia. When it appears together with Alzheimer's disease, which it does quite often, it is called "Mixed dementia". Learn what causes it and how to identify different types.



Vascular Dementia and Vascular Cognitive Impairment


Vascular dementia and vascular cognitive impairment (VCI) are caused by injuries to the vessels supplying blood to the brain. These disorders can be caused by brain damage from multiple strokes or any injury to the small vessels carrying blood to the brain. Dementia risk can be significant even when individuals have suffered only small strokes. Vascular dementia and VCI arise as a result of risk factors that similarly increase the risk for cerebrovascular disease (stroke), including atrial fibrillation, hypertension, diabetes, and high cholesterol. Vascular dementia also has been associated with a condition called amyloid angiopathy, in which amyloid plaques accumulate in the blood-vessel walls, causing them to break down and rupture. Symptoms of vascular dementia and VCI can begin suddenly and progress or subside during one’s lifetime.

Some types of vascular dementia include:

Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL). This inherited form of cardiovascular disease results in a thickening of the walls of small- and medium-sized blood vessels, eventually stemming the flow of blood to the brain. It is associated with mutations of a specific gene called Notch3, which gives instructions to a protein on the surface of the smooth muscle cells that surround blood vessels. CADASIL is associated with multi-infarct dementia, stroke, migraine with aura (migraine preceded by visual symptoms), and mood disorders. The first symptoms can appear in people between ages 20 and 40. Many people with CADASIL are undiagnosed. People with first-degree relatives who have CADASIL can be tested for genetic mutations to the Notch3 gene to determine their own risk of developing CADASIL.

Multi-infarct dementia. This type of dementia occurs when a person has had many small strokes that damage brain cells. One side of the body may be disproportionally affected, and multi-infarct dementia may impair language or other functions, depending on the region of the brain that is affected. Doctors call these “local” or “focal” symptoms, as opposed to the “global” symptoms seen in AD that tend to affect several functions and both sides of the body. When the strokes occur on both sides of the brain, however, dementia is more likely than when stroke occurs on one side of the brain. In some cases, a single stroke can damage the brain enough to cause dementia. This so-called single-infarct dementia is more common when stroke affects the left side of the brain—where speech centers are located—and/or when it involves the hippocampus, the part of the brain that is vital for memory.

Subcortical vascular dementia, also called Binswanger’s disease. This is a rare form of dementia that involves extensive microscopic damage to the small blood vessels and nerve fibers that make up white matter, the “network” part of the brain believed to be critical for relaying messages between regions. The symptoms of Binswanger’s are related to the disruption of subcortical neural circuits involving short-term memory, organization, mood, attention, decisionmaking, and appropriate behavior. A characteristic feature of this disease is psychomotor slowness, such as an increase in the time it takes for a person to think of a letter and then write it on a piece of paper.

Other symptoms include urinary incontinence that is unrelated to a urinary tract condition, trouble walking, clumsiness, slowness, lack of facial expression, and speech difficulties. Symptoms tend to begin after age 60, and they progress in a stepwise manner. People with subcortical vascular disease often have high blood pressure, a history of stroke, or evidence of disease of the large blood vessels in the neck or heart valves. Treatment is aimed at preventing additional strokes and may include drugs to control blood pressure.

older coupleMixed Dementia


Autopsy studies looking at the brains of people who had dementia suggest that a majority of those age 80 and older probably had “mixed dementia,” caused by both AD-related neurodegenerative processes and vascular disease-related processes. In fact, some studies indicate that mixed vascular-degenerative dementia is the most common cause of dementia in the elderly. In a person with mixed dementia, it may not be clear exactly how many of a person’s symptoms are due to AD or another type of dementia. In one study, approximately 40 percent of people who were thought to have AD were found after autopsy to also have some form of cerebrovascular disease. Several studies have found that many of the major risk factors for vascular disease also may be risk factors for AD.

Researchers are still working to understand how underlying disease processes in mixed dementia influence each other. It is not clear, for example, if symptoms are likely to be worse when a person has brain changes reflecting multiple types of dementia. Nor do we know if a person with multiple dementias can benefit from treating one type, for example, when a person with AD controls high blood pressure and other vascular disease risk factors.

See More Vascular Dementia Videos and Articles

Monday, February 09, 2015

Women make up 72 per cent of Alzheimer's patients in Canada | CTV News

Women make up 72 per cent of Alzheimer's patients in Canada | CTV News:



'via Blog this'



Ok ladies which is it your Brain or your chest? I know I sound like a broken record but us with Alzheimer's tend to repeat ourselves alot.



God Bless,

joe

Saturday, January 24, 2015

I am sure this will piss off many.

I am sure this will piss off many. But kiss my ass. For years I have been trying my damndest  to get something done for us that suffer one or another form of Dementia, you know the killer with millions and no survivors.

So one transgender girl goes out and steps in front of a truck and commits suicide and the world suddenly says OOOOOH these people need help. Amazon.com in tribute to her is offering new customers Prime for one yea at $72.00 in her honor. Well fuck me please.

I can understand her wanting to leave a life that is fucked up for her. See I feel the same about mine, but when I expressed that feeling in an HBO documentary The Alzheimer's Project, you can find a link to it on my blog, I was chastised by I cannot tell you how many people. It is a wonderful and selfless act she has preformed to bring attention to her plight, but for me to do the same thing OH NO, i am selfish, I would run family lives, etc. Well what the hell did she do.

This is not a shame on her post, I understand her wanting to leave a life she could nolonger live in or function in. I feel that pain daily and have for 10 years. This is a SHAME on YOU post for not helping us that are dying daily from our disease. Yes all the so called Alzheimer groups out there and our government who cannot get their heads out of their asses.

Leelah Alcorn is now free of her torment. May God keep her close and wrapped in his arms, I for one feel the pain she had. I have now found out that that I have vascular calcification taking place in my muscle tissue in both my kneck and spine, oooh goody now I am a real hard head. This only leads to stroke, death and if I am truly lucky Vascular Dementia, I will have a trifecta, Alzheimer's, Frontal Temporal Dementia and Vascular Dementia.  Is it ok with you now if i still am considering setting my self free?

NOW WHEN DO YOU ALL GET OFF YOUR FLAT BUTTS AND HELP US? 

God Bless & Keep You & This Country of Ours!
joe

Thursday, January 15, 2015

The State of Alzheimer''s



Joseph,
In just five days, President Obama will deliver the State of the Union address. Washington and the nation will pause to hear the president’s vision, and we need him to publicly commit to stopping Alzheimer’s. The nation already has adopted a national plan that sets as goal one preventing and treating Alzheimer’s by 2025. But this is now just 10 years away and much work remains.
President Obama could issue a “moon shot” for ending Alzheimer’s, like John F. Kennedy did for a moon landing in 1961. But it won’t happen absent a relentless push by those impacted by this dreaded disease.
Help us plant a flag for ending Alzheimer’s by adding your voice now. Join with our USAgainstAlzheimer’s networks and thousands of activists nationwide to encourage the president to address Alzheimer’s during his speech.
The annual global cost of treating Alzheimer’s in 2010 was an estimated $604 billion – one percent of global GDP. Without new treatments, the number of Alzheimer’s cases and its associated costs are predicted to quadruple in the next 40 years.
That’s not even mentioning the personal toll it takes on families. More than 5 million Americans suffer from this cruel, unforgiving disease, and their loved ones suffer along with them.
We can’t wait for action. If we are going to stop this terrifying trajectory, we need to get bold. We need leadership.
President Obama has a chance to cast a vision for ending Alzheimer’s during his speech. We need to let him know how important it is that he does.
There’s a path to a cure, but it demands commitment from everyone. If we get it, we’ll beat this disease.
Thank you,
George


empowered by Salsa
God Bless & Keep You & This Country of Ours!
joe

Monday, December 29, 2014

Dr. Brett Osborn

Anti-Aging  -  Oct 8, 2014
 
I believe an analog of metformin will one day launch as an “anti-aging” drug due to its potentially life-extending effects.

Why? Read on. 
4
1
Frank Rummel's profile photoMichelle Jones's profile photo
Frank Rummel
Oct 8, 2014
+
1
2
1
 
 
The controversial study in question here (Can people with type 2 diabetes live longer than those without?  A comparison of mortality in people initiated with metformin or sulphonylurea monotherapy and matched, non-diabetic controls by C. A. Bannister et al) was published behind a paywall in the journal Diabetes, Obesity and Metabolism. For a critique of this story, consider what Prof Kevin McConway, Professor of Applied Statistics, The Open University, said:

“The title of this paper itself is not helpful in that anyone reading it might get the wrong idea – this study cannot actually answer the question it poses (“Can people with type 2 diabetes live longer than those without?”) for reasons discussed below, and it sounds almost as if there are grounds to advise people without diabetes to take metformin. But in fact the study isn’t saying that at all.

“In the press release, Craig Currie says “People lose on average around eight years from their life expectancy after developing diabetes” and goes on to explain why. So if the life expectancy of people with type 2 diabetes is so much shorter, how on earth can they “live longer than people without the disease”, as the title of the release and the paper both say?

“The answer is that the comparison in the paper runs only over the time period when the patients with diabetes were on first-line treatment with metformin, on its own (and there’s a similar comparison involving patients whose first-line treatment is with sulphonylureas). At some point after this first-line treatment starts, many of the patients with diabetes would be switched from metformin alone onto a second-line treatment, and this switch is (or should be) necessary because the diabetes or its effects have got worse. But at that point the comparison in this study simply stops.

“So the quote in the press release about an eight year reduction in life expectancy, in people who develop type 2 diabetes, is talking about the entire rest of a person’s life after the diagnosis, including the time when they might be on a more aggressive second-line treatment. But the comparison in the paper is looking only at the time before the treatment changes. You can’t fit all that into a simple headline, but it is important to note that the story here is not so simple.

“But, if the survival for people with diabetes, taking metformin, is significantly better than the survival for people without diabetes, even just over the limited timespan of this study, might that still not mean that people without diabetes should take metformin in order to live longer than they otherwise would? No, it’s not saying that. The apparent difference might be due to something other than the metformin.

“The researchers did match the controls with patients with diabetes in certain ways, and in their statistical analysis they try to allow statistically for other differences between the people with diabetes and the controls. But the paper itself points out some issues. The researchers could not take into account certain possible confounders (other variables that might affect the comparison) because they did not have data on them for enough of the controls. Even without that important issue, statistical adjustment for confounders is never perfect. The difference in survival between people with diabetes on metformin, and controls without diabetes, was statistically significant but in fact rather small, and probably within the range where it could be explained by residual confounding (that is, the effect of other variables that was not taken into account by the analysis).

“Further, the paper itself also points out that people with diabetes are more likely be monitored for, and receive interventions for, problems with the heart and circulation. This extra intervention and monitoring, and the possibility of residual confounding, between them cast huge doubt on the possibility that the better survival in the patients taking metformin, compared to controls without diabetes, was simply because they were taking metformin.

“Metformin does come out well in comparison to the other diabetes treatment looked at in the study, sulphonylureas, where survival does seem to be clearly worse than it is for control people without diabetes (the paper mentions that metformin is not suitable for some people with diabetes, hence the use of sulphonylureas).  Comparing such patients with people without diabetes does not tell us much about whether it is right to prescribe them sulphonylureas. To investigate that, one would need to compare them with patients taking some other treatment that would also be appropriate for them (and not metformin, which is not appropriate for them), and this study didn’t look at that at all.”

Source:

http://www.sciencemediacentre.org/expert-reaction-to-study-looking-at-type-2-diabetes-metformin-and-lifespan/

I found this to be quite interesting and wanted to pass it on. Info is from a Google+ group I belong to.

God Bless & Keep You & This Country of Ours!!!!
joe